ASCO GU 2023: Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC)
Very interesting MIBC trial by Galsky et al. evaluating gemcitabine, cisplatin, nivolumab after TURBT, which was associated with clinical CR rate 43%. Standardized clinical response assessment with complete CR definition identified patients with favorable oncologic outcomes despite bladder preservation. Results support further studies of personalized strategies in the management plan of localized MIBC, utilizing risk stratification based on clinical response assessment. Optimization of clinical staging using several tools can be a key in that effort.
